Autism SpeaksAutism Speaks Inc. Non Profit Corporation, Princeton, NJ, United States
Autism Speaks is dedicated to promoting solutions, across the spectrum and throughout the life span, for the needs of individuals with autism and their families through advocacy and support; increasing understanding and acceptance of people with autism spectrum disorder; and advancing research into causes and better interventions for autism spectrum disorder and related conditions.
Autism Speaks enhances lives today and is accelerating a spectrum of solutions for tomorrow.
Role in AIMS-2-TRIALS
Autism Speaks plans to contribute Training Materials and Materials for Families from both Autism Speaks and the Autism Speaks Autism Treatment Network (ATN). Joint collaborative activities include: patient/public involvement, dissemination & communication – including translation and co-production of tool kits and exploring the use of ECHO Autism and Educational programming.
Dr Frazier of Autism Speaks is involved in AIMS-2-TRIALS. His research has focused on improving autism identification; developing and studying new treatment approaches; creating and refining measures for tracking autism symptoms and quality of life in individuals and families affected by autism; and translational studies of a genetic sub-group of individuals with autism and phosphatase and tensin homolog (PTEN) mutations.
Dean M. Hartley, Ph.D., is the Senior Director of Genomic Discovery and Translational Science at Autism Speaks. In this role, he oversees programs to advance the understanding of Autism Spectrum Disorder (ASD) genetics through the AGRE and MSSNG programs as well as facilitating the testing of potential treatments through the Preclinical Autism Consortium for Therapeutics (PACT).
Also involved in the project is Dr Murray. She is a clinician specialising in program development, diagnosis and treatment of individuals with autism. Dr Murray’s research includes studies examining language, social skills, diagnosis and impact of co-occurring medical conditions in autism. Dr Murray’s current focus includes using quality-improvement science and research to improve clinical care and outcomes for children with autism and emphasises the dissemination and implementation of evidence-based, best-practice findings.
Chief Science Officer
Senior Director, Genomic Discovery and Translational Science
Vice President of Clinical Programs